The company’s weight loss therapy was able to sustain itself for up to 40 days in obese patients after a single injection.

Gilead presented the data at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). Image credit: Shutterstock / Sundry Photography Gilead is set to launch a Phase III trial of its ...

Whilst OSE has not yet released full results from the trial, the company has said that the trial met its OS goal showing positive outcomes. Credit: Shutterstock / Jo Panuwat D. OSE ...